Immune Pharmaceuticals Stock Fundamentals
Immune Pharmaceuticals fundamentals help investors to digest information that contributes to Immune Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Immune OTC Stock. The fundamental analysis module provides a way to measure Immune Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immune Pharmaceuticals otc stock.
Immune |
Immune Pharmaceuticals OTC Stock Shares Outstanding Analysis
Immune Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Immune Pharmaceuticals Shares Outstanding | 72.38 M |
Most of Immune Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immune Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Immune Pharmaceuticals has 72.38 M of shares currently outstending. This is 59.91% lower than that of the Healthcare sector and 94.3% lower than that of the Drug Manufacturers - Major industry. The shares outstanding for all United States stocks is 87.34% higher than that of the company.
Immune Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immune Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Immune Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immune Pharmaceuticals competition to find correlations between indicators driving Immune Pharmaceuticals's intrinsic value. More Info.Immune Pharmaceuticals is currently regarded as number one stock in return on asset category among related companies. It is considered the number one company in current valuation category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immune Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immune Pharmaceuticals' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immune Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Immune Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immune Pharmaceuticals' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Immune Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Immune Pharmaceuticals by comparing valuation metrics of similar companies.Immune Pharmaceuticals is currently under evaluation in shares outstanding category among related companies.
Immune Fundamentals
| Return On Asset | -42.63 | |||
| Current Valuation | 8.67 M | |||
| Shares Outstanding | 72.38 M | |||
| Shares Owned By Insiders | 2.16 % | |||
| Shares Owned By Institutions | 0.06 % | |||
| Number Of Shares Shorted | 1.08 M | |||
| Price To Earning | (0.17) X | |||
| Price To Book | 0.40 X | |||
| Price To Sales | 858.11 X | |||
| Revenue | 19 K | |||
| EBITDA | (13.77 M) | |||
| Net Income | (34.39 M) | |||
| Cash And Equivalents | 76 K | |||
| Total Debt | 8.33 M | |||
| Debt To Equity | 989.50 % | |||
| Current Ratio | 0.02 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (14.69 M) | |||
| Short Ratio | 1.32 X | |||
| Earnings Per Share | (1.15) X | |||
| Beta | 2.99 | |||
| Market Capitalization | 553.21 K | |||
| Total Asset | 36.18 M | |||
| Retained Earnings | (62.99 M) | |||
| Working Capital | (1.45 M) | |||
| Current Asset | 4.83 M | |||
| Current Liabilities | 6.29 M | |||
| Z Score | -1.4 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immune Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immune Pharmaceuticals' short interest history, or implied volatility extrapolated from Immune Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Immune OTC Stock
If you are still planning to invest in Immune Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Pharmaceuticals' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |